RE:RE:Could The Ellipses Leak Force a Plan B? "SunRock will continue to be involved in the development of EP0017 to ensure efficient translational activities through a service agreement with Ellipses. If Ellipses out-licences EP0017, SunRock will also receive milestone payments and royalties."
Midatech has an already existing cancer team given it's a clinical stage company and with scale can spread cost over more than one cancer program with an Ellipses agreement. It could more efficiently support a services agreement with Ellipses. If the Biodexa deal is completed first then the company could be on a sound financial footing and with the scale to support more fulsomly support a cancer agreement with Ellipses as Biodexa also develops its own pipeline of therapeutics for rare diseases. As it stands now BTI is a handful of people with a lead xB3 program in Lysosomal Storage Disorders that is potentially years from clinical trials, no cancer infrastructure, and BTI is in debt with no cash runway to support a multi-year agreement. Biodexa would be in a position to support a strong deal. Perhaps Ellipses could also be interested in Midatech's cancer assets like Q-Sphera and its lead glioblastoma asset, etc. Midatech's CEO said there was some tumor data expected early in the year for Q-Sphera. Q-Sphera coud 'hold' the drug in the tumor longer thereby increasing the effective dose in the tumor over time to enhance efficacy. Tumors can be quite leaky. Q-Sphera can also create a drug that is injectable vs. an IV drug and that leads to a number of benefits for the patient, and healthcare system.